Back to discover
Drug

Becatecarin

Late-stage clinical development
ClassDNA topoisomerase I inhibitor

Also known as 6-(2-(DIETHYLAMINO)ETHYL)-REBECCAMYCIN, DEAE-rebeccamycin.

RxNorm815362ChEMBLCHEMBL2107313UNIIA60X6MBU6G
3
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase I and Pharmacokinetic Study of Sequences of NSC 655649 (Rebeccamycin Analogue) and Cisplatin Without and With Granulocyte Colony-Stimulating Factor Support Every 21 Days

Clinical trial2013-02-11Completed · ClinicalTrials.gov

A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)

Clinical trial2013-02-11Completed · ClinicalTrials.gov

A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors

Clinical trial2013-02-05Completed · ClinicalTrials.gov

A Randomized Phase 2 Study of Rebeccamycin Analog in Advanced Breast Cancer

Clinical trial2013-02-01Completed · ClinicalTrials.gov

A Phase I Study Of XL119 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase

Clinical trial2013-01-23Completed · ClinicalTrials.gov

A Phase I Study of XL119 (Rebeccamycin Analogue) in Combination With Oxaliplatin in Patients With Refractory Solid Tumors

Clinical trial2013-01-10Terminated · ClinicalTrials.gov

Phase II Trial of XL119 (Rebeccamycin Analogue) in Relapsed "Sensitive" Small Cell Lung Cancer

Clinical trial2008-04-01Terminated · ClinicalTrials.gov

A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery

Clinical trial2006-11-01Terminated · ClinicalTrials.gov

A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma

Clinical trial2006-09-01Completed · ClinicalTrials.gov

Phase II and Pharmacokinetic Trial of Rebeccamycin Analog in Hepatobiliary Cancers

Clinical trial2005-11-01Terminated · ClinicalTrials.gov

A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer

Clinical trial2005-03-01Completed · ClinicalTrials.gov

A Randomized Phase II Trial of Two Different Schedules of Administration of Rebeccamycin Analog in Patients With Advanced Non-Small Cell Lung Cancer

Clinical trial2005-01-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Becatecarin
Aliases & brands
6-(2-(DIETHYLAMINO)ETHYL)-REBECCAMYCINDEAE-rebeccamycin
RxNorm CUI
815362
ChEMBL ID
CHEMBL2107313
UNII
A60X6MBU6G
Primary mechanism
DNA topoisomerase I inhibitor

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

DNA topoisomerase 1
TOP1 · P11387
INHIBITORDNA topoisomerase I inhibitor
DNA topoisomerase 2-alpha
TOP2A · P11388
INHIBITORDNA topoisomerase II inhibitor
DNA topoisomerase 2-beta
TOP2B · Q02880
INHIBITORDNA topoisomerase II inhibitor

Clinical trials

13 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
13
registered trials across all phases
LATEST COMPLETION 2007
1
Late-stage (III+)
8
Completed
5
Discontinued
PHASE DISTRIBUTIONn = 13
Phase 13Phase 29Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery

TerminatedPH IIIHelsinn Healthcare SAn=2482006

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase I Study Of XL119 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase

CompletedPH INational Cancer Institute (NCI)n=402007

A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma

CompletedPH IIMemorial Sloan Kettering Cancer Centern=302006

A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors

CompletedPH IINational Cancer Institute (NCI)n=2002006

A Randomized Phase 2 Study of Rebeccamycin Analog in Advanced Breast Cancer

CompletedPH IINational Cancer Institute (NCI)n=422006

A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer

CompletedPH IIBarbara Ann Karmanos Cancer Institute2005

A Randomized Phase II Trial of Two Different Schedules of Administration of Rebeccamycin Analog in Patients With Advanced Non-Small Cell Lung Cancer

CompletedPH IICase Comprehensive Cancer Centern=422005
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials